Addition of genotypic resistance testing did not improve virologic response in patients with HIV virologic failure

A randomized controlled trial found that the addition of genotypic resistance testing to routine care did not improve virologic suppression among persons whose first-line antiretroviral therapy (ART) failed in public-sector HIV clinics in Uganda and South Africa. These results reinforce the critical need for and persistent challenge of finding effective interventions for persons who have virologic failure after ART initiation in the public sector in sub-Saharan Africa. The findings are published in Annals of Internal Medicine.